If your gastroenterologist has prescribed Tremfya for your Crohn's disease and you have an Aetna plan, the short answer is that Aetna does cover it, but coverage runs through a prior authorization process with specific medical necessity criteria. Tremfya, known generically as guselkumab, only earned its Crohn's indication in 2025, so it is one of the newest options in the treatment toolbox. That recency matters because newer biologics tend to sit later in an insurer's preferred sequence, and Aetna documents exactly what it expects in a published Clinical Policy Bulletin. Understanding that document, and how Aetna routes the drug through CVS Caremark and CVS Specialty, is the difference between a smooth approval and a frustrating denial. This article walks through what Aetna's policy actually says and how to position your request.
What Tremfya Is and Why Its Approval Date Matters
Tremfya is an interleukin-23 antagonist, meaning it blocks a signaling protein that drives the inflammation behind Crohn's disease. The US Food and Drug Administration approved Tremfya for adults with moderately to severely active Crohn's disease in 2025, making it the first IL-23 inhibitor to offer both a subcutaneous and an intravenous induction option. The FDA prescribing information lists intravenous induction at 200 mg at Weeks 0, 4, and 8, with subcutaneous maintenance given every eight weeks. Because the Crohn's indication is so new, Aetna and other insurers often treat Tremfya as a later-line agent rather than a first choice, which shapes the coverage questions you will face.
What Aetna's Clinical Policy Bulletin Requires
Aetna spells out its criteria in Clinical Policy Bulletin 1011 for guselkumab, which now lists moderately to severely active Crohn's disease as a covered indication. The bulletin states that the medication must be prescribed by or in consultation with a gastroenterologist, and it requires a documented negative tuberculosis test within twelve months before starting therapy for patients new to biologic drugs. Precertification is required for the intravenous formulation. The bulletin also sets continuation criteria, meaning that ongoing coverage depends on showing clinical improvement such as reduced abdominal pain or improved endoscopic findings. Reading this bulletin alongside your own plan documents tells you what evidence your prescriber needs to assemble before submitting the request.
How Step Therapy Often Enters the Picture
The Clinical Policy Bulletin defines medical necessity, but your specific plan's formulary is where step therapy usually lives. Aetna is a CVS Health company, and it manages pharmacy benefits through CVS Caremark and specialty drugs through CVS Specialty. Many plans place a newer biologic like Tremfya behind preferred agents, asking you to try and fail an older therapy first. This pattern is reinforced by treatment guidance: the AGA Living Clinical Practice Guideline on moderate-to-severe Crohn's disease recommends guselkumab among effective options and actually favors early advanced therapy over prolonged step therapy through corticosteroids and immunomodulators. If your plan still imposes a step, documenting why you cannot use the preferred drug becomes central to your case.
Building the Medical Necessity Case
A strong submission ties your clinical history directly to Aetna's criteria. Because Tremfya is positioned as a later-line agent, the most persuasive requests document inadequate response, loss of response, or intolerance to therapies you have already tried, which is the same population studied in the trials supporting approval. The pivotal GRAVITI study of subcutaneous guselkumab showed clinical remission at week 12 in 56.1 percent of treated patients versus 21.4 percent on placebo, and the GALAXI-2 and GALAXI-3 trials of intravenous induction confirmed durable benefit through 48 weeks. Citing your gastroenterologist's documentation of disease severity, prior treatment failures, and current symptoms gives the reviewer the specific evidence the bulletin asks for.
Verifying Coverage and Appealing a Denial
Before assuming anything, confirm the details that vary by plan.
Whether Tremfya falls under your pharmacy benefit through CVS Caremark or your medical benefit
Your plan's specific step therapy and prior authorization requirements
Your out-of-pocket cost share for a specialty drug
If Aetna denies the request, you have the right to appeal. Aetna's member appeals and grievances process allows you to challenge a coverage decision and, when a denial is based on medical necessity, to request an independent external review for services valued at five hundred dollars or more. Your gastroenterologist can submit a letter of medical necessity restating how your history meets the Clinical Policy Bulletin criteria. The DailyMed prescribing information and your treatment records are the backbone of that appeal.
Putting It Together
Aetna covers Tremfya for Crohn's disease, but coverage is conditional on meeting the criteria in Clinical Policy Bulletin 1011 and clearing whatever prior authorization and step therapy your individual plan imposes. Because the Crohn's indication arrived only in 2025, expect your plan to treat Tremfya as a later-line option and to want documentation of why earlier therapies did not work for you. The most reliable path is to read both the Clinical Policy Bulletin and your own plan documents, have your gastroenterologist build a medical necessity case grounded in your treatment history, and use Aetna's appeals and external review process if the first answer is no. Coverage rules change, so confirm the current criteria directly with Aetna and CVS Caremark before you start.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.